Oral Resveratrol supplementation attenuates exercise-induced Interleukin-6 but not Oxidative Stress after a high intensity cycling challenge in adults

Abstract

Previous studies demonstrated that resveratrol (RES) is able to enhance antioxidant, anti-inflammatory and insulin actions in humans. It is unclear whether RES can be used as ergogenic aids to enhance high-intensity cycling exercise performance and attenuate the high-intensity exercise-induced oxidative stress and inflammation. This study investigated the effect of RES supplementation on oxidative stress, inflammation, exercise-induced fatigue, and endurance performance. Eight male athletes participated in this single-blind crossover designed study and randomly instructed to receive four days of either oral RES (480 mg per day, totally 1920mg) or placebo supplementation. The cycling exercise challenge at 80% maximal oxygen consumption with 60 rpm was performed following 4 days of either RES or placebo supplementation. The total cycling performance time was recorded. In addition, blood samples were obtained to analyze the changes in blood glucose, plasma non-esterified fatty acid, serum lactate dehydrogenase, creatine kinase, uric acid, total antioxidant capacity, malondialdehyde, tumor necrosis factor-α, and interleukin-6. The exhausting time of cycling exercise challenge was not significantly increased in RES compared to that in placebo. However, IL-6 response was significantly decreased during exercise challenge in RES trial, and there were no differences in blood biomarkers, fatigue factors, and antioxidative response. Oral RES supplementation can attenuate exercise-induced IL-6 response but not fatigue and oxidative stress, inflammation response. However, we infer that 4-day oral RES supplementation has no ergogenic property on enhancing the high-intensity cycling exercise performance.

Keywords: antioxidant phytochemicals; cycling exercise; ergogenic property; fatigue.

Figure 1

Experimental design and protocol.

Figure 2

Individuals/average time to exhaustion (TTE) with 80% O_2max exercise challenge after placebo or resveratrol supplementation.

Figure 3

Blood glucose (A) and plasma non-esterified fatty acids (NEFA) (B) concentrations before and during exercise in resveratrol (-●-) and placebo (-○-). B represents before exercise. END represents immediately finishing exercise. END+60 represents 60 minutes after exercise. Values are expressed as mean ± SE, N=8. * Significant difference against placebo (P < 0.05).

Figure 4

Serum lactate dehydrogenase (LDH) (A), creatine kinase (CK) (B) and uric acid (UA) (C) concentrations before and during exercise in resveratrol (-●-) and placebo (-○-). B represents before exercise. END represents immediately finishing exercise. END+60 represents 60 minutes after exercise. Values are expressed as mean ± SE, N=8. * Significant difference against placebo (P < 0.05).

Figure 5

Serum total antioxidant capacity (TAC) (A) and malondialdehyde (MDA) (B) concentrations before and during exercise in resveratrol (-●-) and placebo (-○-). B represents before exercise. END represents immediately finishing exercise. END+60 represents 60 minutes after exercise. Values are expressed as mean ± SE, N=8. * Significant difference against placebo (P < 0.05).

Figure 6

Serum tumor necrosis factor-α (TNF-α) (A) and interleukin-6 (IL-6) (B) concentrations before and during exercise in resveratrol (-●-) and placebo (-○-). B represents before exercise. END represents immediately finishing exercise. END+60 represents 60 minutes after exercise. Values are expressed as mean ± SE, N=8. * Significant difference against placebo (P < 0.05).